1. Home
  2. Companies
  3. BIO
  4. Material Events

Biome Australia (ASX:BIO) — Material Events

ASX:BIO · 16 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 1 article Significant 14 articles Notable 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
14
Biome Australia Surges Past Sales Forecasts with Record $5.94m QuarterMedium
Biome Australia posts record Q1 FY26 sales revenue, beating forecasts and advancing Vision 27 targets
1 Oct 2025 ·Trading Update ·85
Biome Australia to Onshore Activated Probiotics Production with SPA, Targeting Margin and Working Capital GainsMedium
Biome Australia to Onshore Activated Probiotics Production with SPA, Targeting Margin and Working Capital Gains
3 June 2026 ·Commercial Manufacturing Agreement Announcement ·85
Biome Australia Reports Record $23.9m Sales in FY26, Eyes International GrowthMedium
Biome Australia reports record $23.9m FY26 sales, 30% growth, on track for Vision 27 targets
1 July 2026 ·Trading Update ·85
Biome Australia Hits 1 Million Probiotic Boxes Sold and Expands International ReachMedium
Biome Australia hits 1 million probiotic boxes sold, expands internationally, and expects FY26 profit
28 Apr 2026 ·Quarterly Activities & Appendix 4C ·85
Biome Surges to Record $5.94m Q1 Revenue, Seventh Straight Positive EBITDAMedium
Biome posts record $5.94m Q1 revenue and seventh consecutive positive EBITDA
17 Oct 2025 ·Quarterly Activities & Appendix 4C ·85
Biome Australia Posts Record $6.5m Q2 Sales and Eighth Straight Positive EBITDAMedium
Biome Australia posts record Q2 sales revenue of $6.5m and eighth consecutive positive EBITDA quarter
27 Jan 2026 ·Quarterly Activities & Appendix 4C ·85
Biome Australia Surges with 40% Revenue Growth and 172% Profit JumpMedium
Biome Australia posts 40% revenue growth and 172% profit surge in H1 FY26
23 Feb 2026 ·Appendix 4D Half-year report ·85
Biome Australia Sets New Sales Records and Advances Onshore ManufacturingMedium
Biome Australia reports record FY26 sales, onshore manufacturing deal, and expanded probiotic clinical trial
29 July 2026 ·Quarterly Activities and Appendix 4C ·85
Biome Australia Nears Breakeven with $1.8m International Revenue and New Manufacturing HubMedium
Biome Australia FY26 update shows international growth, near breakeven, and new manufacturing and digital platform launches
27 July 2026 ·Investor Update ·80
Biome Launches Groundbreaking Clinical Trial for Gut Health ProbioticMedium
Biome launches first human clinical trial for proprietary probiotic BMB18 targeting gut health
15 Dec 2025 ·ASX Announcement ·80
Biome Australia Surges with Record 40% Sales Growth in Q2 FY26Medium
Biome Australia posts record Q2 and H1 FY26 sales with over 40% growth
5 Jan 2026 ·Trading Update ·75
Biome Secures Fullscript Deal to Unlock Canadian Practitioner MarketMedium
Biome Secures Fullscript Distribution Partnership to Expand Canadian Market Reach
2 Feb 2026 ·ASX Announcement ·75
Biome Files Patent for Probiotic BMB18 Ahead of Clinical Trial LaunchMedium
Biome Files Patent for Next Gen Probiotic BMB18, Clinical Trial to Start Q4 FY26
27 Apr 2026 ·Patent Filing and Clinical Trial Announcement ·75
Biome Australia Expands BMB18 Trial to Top-Ranked Greek UniversityMedium
Biome Australia launches international multi-centre clinical trial for proprietary probiotic BMB18
27 May 2026 ·Clinical Trial Commencement Announcement ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.